Lotus Lake Ventures

Lotus Lake Ventures is a venture capital investment firm based in Beijing, China, associated with Tsinghua University. The firm specializes in investing in early-stage and growth-stage companies within the science and technology sectors. Its focus areas include technology, media, telecommunications, new materials, life sciences, and clean technology, targeting enterprises that demonstrate core competitiveness and innovation.

Tao Jiang

Investment Director

Ke Yu

Investment Director

Fuqiang Zhao

Investment Director

Jiman Zhu Ph.D

Principal

60 past transactions

iRegene

Series B in 2025
iRegene is a company dedicated to researching and developing pharmaceutical therapies for neurodegenerative and rare diseases. It specializes in a new generation of chemically defined cell therapies, utilizing a chemical induction system that facilitates the generation of high-purity human cell types. This innovative approach aims to provide effective treatments for conditions such as Parkinson's disease and certain forms of blindness, thereby enhancing the options available to healthcare professionals in their patient care. Through its commitment to advancing medical science, iRegene seeks to address significant unmet needs in the treatment of complex diseases.

Juzheng Medical

Series A in 2025
Juzheng Medical develops medical device products, specializing in the study, creation, and manufacturing of medical devices. It is committed to providing innovative medical devices for vascular interventional treatments.

Qingwei Rufeng Technology

Seed Round in 2024
Qingwei Rufeng Technology is an autonomous vehicle company that offers solutions for unmanned and digitalized airport logistics transportation.

Reprogenix

Series A in 2024
Reprogenix is a groundbreaking medical technology firm that began with stem cell therapy for diabetes and is dedicated to expanding the use of cell therapy in a wide range of disease areas.

Huiyue Medical

Seed Round in 2024
Huiyue Medical focuses on the development, production and sales of artificial intelligence surgical robots.

Better MedTech

Seed Round in 2024
Better Medtech specializes in innovative solutions for urinary and pelvic floor health. The company focuses on the research and development, production, and sales of specialized medical devices aimed at addressing conditions such as benign prostatic hyperplasia, urinary incontinence, and kidney stones, as well as novel tumor therapies. By providing advanced medical technology and equipment, Better Medtech supports healthcare providers with effective instrument solutions tailored to meet the needs of patients and enhance medical care.

Juzheng Medical

Seed Round in 2023
Juzheng Medical develops medical device products, specializing in the study, creation, and manufacturing of medical devices. It is committed to providing innovative medical devices for vascular interventional treatments.

Kanova

Series B in 2023
Kanova is a biopharmaceutical company dedicated to the development of therapeutic antibodies and innovative combination therapies targeting immuno-oncology and autoimmune diseases. The company offers a biomedical technology service platform that supports pharmaceutical research and production in biotechnology. It specializes in antibody-based drugs that enhance immune system function, along with providing technical consultation and drug quality inspection services. By focusing on these areas, Kanova aims to help clients improve drug quality and advance the discovery of new biomedicine efficiently.

Yanming Biology

Series A in 2023
Pyrotech pharmaceuticals is a biotechnology company that focuses om development for drugs for the treatment of inflammation and tumors.

Sinotau

Series E in 2023
SinoTau is a comprehensive solution provider focused on both generic and innovative pharmaceuticals. The company specializes in the early development of antibody biopharmaceuticals and conducts research on a range of medications aimed at treating cancers, neurological disorders, and autoimmune diseases. With expertise in medicinal chemical synthesis, generic drug analysis, and pharmaceutical preparations, SinoTau supports the biotechnology industry through targeted drug development. Their work is underpinned by advanced diagnostic technologies and monoclonal antibody innovations, positioning them as a key player in the fields of cardiovascular health, neurodegeneration, and oncology.

VDJ

Series C in 2023
VDJ is an antibody affinity enhancement platform that simulates the maturation mechanism of human antibodies and is specialized in autoimmune diseases. Their products include IL-6R antibodies and CTLA-4-Ig. They serve markets.

Sijian Bio

Series A in 2023
Sijian Bio is a progressive antibody research and development firm.

Hongyun Biotech

Series B in 2023
Hongyun Biotech is a biotech company that promotes therapeutic innovation based on structural pharmacology.

Cygnus Bio

Series C in 2023
Cygnus Biosciences (Beijing) Co., Ltd. is a biotechnology firm focused on the research and development of gene sequencing platforms. The company aims to advance clinical medicine through improved screening and diagnostic capabilities. By leveraging innovative gene sequencing technology, Cygnus provides accurate and efficient solutions for genetic engineers and gene therapy specialists, enabling them to obtain reliable data for their research. This commitment to industrialization and application of gene sequencing facilitates effective and error-free experimentation, ultimately enhancing the overall quality of biotech research and medical diagnostics.

Care

Series A in 2023
Care is a medical technology company focused on developing solutions for neurological diseases. The company engages in research and development of intelligent tools, including software, hardware, and artificial intelligence technologies, aimed at improving the screening, diagnosis, treatment, and research of neurological conditions. Through its innovative approach, Care seeks to enhance the understanding and management of these complex diseases, contributing to advancements in medical care and patient outcomes.

UGa Technology

Series A in 2023
UGa Technology's research and development of GaN RF chips for the next generation of wireless communication equipment They provide solutions for the booming wireless communication industry. They also provide compound semiconductor devices. They can also be adapted to other RF device manufacturers’ products.

Singular Medical

Series B in 2023
Singular Medical is a technology company focused on the research, development, and industrialization of cardiac rhythm management (CRM) products. The company designs and develops a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. Singular Medical aims to provide reliable and professional medical equipment that addresses the needs of a large population of cardiac patients, offering solutions that span from initial detection to ongoing follow-up care.

Beijing Huaguan Biotechnology

Series B in 2022
Beijing Huaguan Biotechnology specializes in providing integrated drug research and development services, primarily focusing on small molecules and antibody-drug conjugates (ADCs). The company is recognized for its highly skilled and experienced team, which is equipped with advanced experimental technology to facilitate pre-clinical pharmaceutical research. Huaguan Biotechnology serves a diverse clientele, including prominent domestic pharmaceutical firms like Sihuan Pharmaceutical and Sichuan Kelun, as well as innovative technology enterprises such as Suzhou Amate and Jiangsu Ya Sheng. The company’s reputation for effective team development and service quality has garnered recognition within the industry, attracting investments from listed companies.

ICE Bioscience

Series B in 2022
ICE Bioscience Inc. is a contract research organization based in Beijing, China, specializing in preclinical research solutions for electrophysiology and early drug discovery services. Founded in 2010, the company focuses on the development of ion channel-related pharmaceuticals, particularly targeting the neuronal and cardiovascular systems. ICE Bioscience offers a range of services, including ion channel profiling, cardiac safety panels, brain slice screening, and various molecular biology applications. The company has established proprietary ion channel cell lines for both voltage-gated and ligand-gated channels. Additionally, it maintains a diverse platform for target-based panel screening, supporting drug discovery across multiple therapeutic areas such as immunology, oncology, and CNS diseases. ICE Bioscience is committed to enhancing the drug discovery process through effective communication and flexible collaboration models, aiming to identify and validate drug targets and streamline the progression from compound screening to preclinical candidate selection.

China Immunotech

Series B in 2022
China Immunotech is a research and development company specializing in innovative small molecule drugs and cellular immunotherapy. Founded in March 2018 by renowned immunologists, the company focuses on developing immune cell therapy technologies, including CAR-T and TCR-T cell therapies, which are supported by independent intellectual property rights. China Immunotech aims to advance the commercialization of these therapies to treat various diseases, particularly targeting hematological tumors. Its unique technology platforms, STAR-T and TCR-T, are designed to provide effective treatment options for patients while also addressing the challenge of tumor recurrence.

Zhenzhi Yixue Keji

Seed Round in 2021
Zhenzhi Yixue Keji is a tumor immunotherapy technology developer.

NeuralGalaxy

Series A in 2021
Neural Galaxy is a brain science company that emerged from Harvard Medical School and the Massachusetts Institute of Technology. The organization focuses on addressing brain disorders through advanced software and hardware technologies. By leveraging breakthrough research in brain science, Neural Galaxy aims to enhance understanding of the brain and high-level intelligence. Its mission includes tackling significant challenges related to brain diseases and improving treatment options, ultimately contributing to a deeper comprehension of human cognition and enhancing overall societal intelligence.

Kanova

Series B in 2021
Kanova is a biopharmaceutical company dedicated to the development of therapeutic antibodies and innovative combination therapies targeting immuno-oncology and autoimmune diseases. The company offers a biomedical technology service platform that supports pharmaceutical research and production in biotechnology. It specializes in antibody-based drugs that enhance immune system function, along with providing technical consultation and drug quality inspection services. By focusing on these areas, Kanova aims to help clients improve drug quality and advance the discovery of new biomedicine efficiently.

Chinagene Tech

Seed Round in 2021
Beijing Zhongyin Technology Co., Ltd. is a professional enterprise engaged in the research and development of clinical genetic diagnosis, prevention and gene therapy for hereditary eye diseases. The company's clinical genetic diagnosis platform for hereditary eye diseases can provide fast, accurate, reliable and professional clinical genetic diagnosis services for hereditary ophthalmology patients.

Slichem

Series A in 2021
Slichem is a manufacturer based in Shijiazhuang, China, specializing in the development of liquid crystal materials and fine chemicals. The company focuses on producing display materials, including liquid crystal materials and OLED materials, which are essential components in various display technologies. Through its expertise in this field, Slichem aims to meet the growing demand for high-quality materials used in modern electronic displays.

Venmedtech

Series B in 2021
Venmedtech produces testing, inspection, and processing equipment. They engaged in the research and development of production and sales of interventional devices related to venous vascular diseases.

Chinagene Tech

Seed Round in 2021
Beijing Zhongyin Technology Co., Ltd. is a professional enterprise engaged in the research and development of clinical genetic diagnosis, prevention and gene therapy for hereditary eye diseases. The company's clinical genetic diagnosis platform for hereditary eye diseases can provide fast, accurate, reliable and professional clinical genetic diagnosis services for hereditary ophthalmology patients.

Sinotau

Series C in 2020
SinoTau is a comprehensive solution provider focused on both generic and innovative pharmaceuticals. The company specializes in the early development of antibody biopharmaceuticals and conducts research on a range of medications aimed at treating cancers, neurological disorders, and autoimmune diseases. With expertise in medicinal chemical synthesis, generic drug analysis, and pharmaceutical preparations, SinoTau supports the biotechnology industry through targeted drug development. Their work is underpinned by advanced diagnostic technologies and monoclonal antibody innovations, positioning them as a key player in the fields of cardiovascular health, neurodegeneration, and oncology.

Insight Lifetech

Series B in 2020
Insight Lifetech is a medical technology company focused on creating innovative solutions for the diagnosis and treatment of cardiovascular diseases. It has developed a synergistic platform that integrates research and development, manufacturing, and commercialization, which enhances collaboration, accelerates product development, and promotes cost efficiency. The company is notable for creating the first and only domestic fractional flow reserve (FFR) system in China that has received approval from the National Medical Products Administration (NMPA). By manufacturing high-quality medical devices that feature reliable precision diagnostics and therapeutic capabilities, Insight Lifetech aims to empower physicians to improve patient outcomes and save lives.

OptoMedic

Series C in 2020
OptoMedic specializes in the research, development, and production of advanced optical medical devices and systems. The company focuses on creating medical fluorescence navigation endoscopes that utilize aerospace and military optical technology for applications in healthcare. Its product offerings include endoscopic monitoring equipment, cancer screening tools, endoscopic navigation systems, and fluorescent imaging systems. These innovations enable medical institutions and healthcare providers to effectively observe and assess patient conditions, enhancing diagnostic capabilities and treatment outcomes.

Sensylink

Series B in 2019
Sensylink Microelectronics Co., Ltd. specializes in the design, development, manufacturing, and marketing of environmental sensor integrated circuits (ICs), including those for temperature, humidity, and gas detection. The company focuses on creating compact and energy-efficient sensors that enable enterprises to enhance their measurement devices. Sensylink's products are characterized by high precision, miniature size, low power consumption, and cost-effectiveness, achieved through the integration of innovative sensor technology with advanced IC design and processing techniques. Based in China, Sensylink aims to provide customers worldwide with reliable and economical environmental sensor components and services.

Lidakang Technology

Series A in 2019
Beijing Lidakang Technology specializes in the development and manufacturing of artificial joints for surgical implants. The company provides a range of products and systems designed for hip, knee, and various bone areas, ensuring high-quality surgical joint implants for healthcare professionals. Lidakang Technology aims to enhance patient outcomes through innovative solutions in the orthopedic field.

RealAI

Angel Round in 2019
RealAI is an artificial intelligence technology firm that offers a range of innovative solutions aimed at enhancing operational efficiency across different industries. The company specializes in financial smart risk control and management, as well as advanced systems such as facial recognition technology. Additionally, RealAI's offerings include industrial vision inspection, predictive equipment maintenance, and optimization of equipment operation parameters. Through these technologies, RealAI aims to assist enterprises in improving their overall control and efficiency in operations.

Hanyu Medical

Series B in 2018
Hanyu Medical is a pioneering company in the development, production, and sale of transcatheter mitral valve repair devices, focusing on innovative solutions for heart valve diseases. Its primary product, Valve Clamp, is an interventional device designed for minimally invasive treatment of mitral valve regurgitation. This device facilitates the closure of heart valves during operations, allowing surgeons to perform heart surgeries with reduced invasiveness. Hanyu Medical's commitment to advancing medical technology positions it as a significant player in the cardiovascular device market.

Kanova

Series A in 2018
Kanova is a biopharmaceutical company dedicated to the development of therapeutic antibodies and innovative combination therapies targeting immuno-oncology and autoimmune diseases. The company offers a biomedical technology service platform that supports pharmaceutical research and production in biotechnology. It specializes in antibody-based drugs that enhance immune system function, along with providing technical consultation and drug quality inspection services. By focusing on these areas, Kanova aims to help clients improve drug quality and advance the discovery of new biomedicine efficiently.

Chinac.com

Series E in 2018
Chinac.com is a prominent Chinese cloud computing infrastructure operator that specializes in the research, development, and management of commercial cloud computing solutions. The company offers a range of IT services, including cloud storage and computing infrastructure, catering to both domestic and international clients. Chinac.com operates as a provider of Software as a Service (SaaS) and Platform as a Service (PaaS), while also engaging in traditional software development and system integration. The firm supports a diverse array of sectors, including online gaming, e-commerce, mobile internet, online education, and social networking. With tens of thousands of physical server clusters and 20 data centers across more than 15 cities, Chinac.com boasts a robust network that encompasses major telecommunications providers.

Kiwi Green Technologies

Series A in 2018
Kiwi Green Technologies is a developer of recycling and environmental energy technologies. The company specializes in converting waste into new energy, offering solutions that enable both government and corporate clients to produce green and renewable energy. By focusing on recycling and energy generation, Kiwi Green Technologies aims to significantly lower the costs associated with treating environmental pollutants, thereby promoting sustainable practices and reducing the ecological impact of waste.

IntEngine

Series A in 2018
IntEngine, operating under Tanjing Technology, specializes in developing software algorithms and chip hardware technology aimed at enhancing efficiency in everyday life. The company focuses on deep learning and machine learning algorithms, providing tailored solutions for various Internet of Things (IoT) terminal devices. In addition to offering advanced digitalization solutions for industrial users, IntEngine develops end-side AI chips that improve the functionality and security of terminal equipment, including upgrades to security monitoring systems. Through its innovative approach, the company supports the growing demand for intelligent and efficient technology in diverse applications.

Sinogene

Series A in 2018
Sinogene is a company that specializes in pet cloning and cell transfer solutions, utilizing somatic cell nuclear transfer technology. It focuses on the cloning and breeding of various types of pets, including working dogs, pet dogs, and purebred breeds, while also offering services for the preservation of somatic cell genes. The company is committed to advancing animal genetic research and believes that improved breeding practices will benefit this field. Sinogene's team comprises scientists, doctors, and veterinary specialists dedicated to providing reliable and effective pet cloning and gene editing services for pet owners.

Cameraking Technology

Angel Round in 2017
Cameraking Technology is the distributor of the Internet of Things and applications to achieve image products. They are capable of designing core devices, integrating the supply chains of various industries, and producing and manufacturing goods. They offer manufacturing services as well as prompt, competent support for imaging technology. Their organization is made up of chip companies, solution providers, the internet of things, AI, and subindustry leaders.

Suzhou Ribo Life Science

Series B in 2017
Suzhou Ribo Life Science Co., Ltd. specializes in the development of nucleic acid drugs utilizing RNA interference (RNAi) technology, with a particular focus on treating liver diseases. Founded in 2007 and based in Kunshan, China, the company engages in various aspects of drug development, including drug discovery, siRNA design and screening, chemical modification, delivery technology, pharmacodynamics and pharmacokinetics studies, safety evaluation, and clinical trials. Suzhou Ribo Life Science offers siRNA therapeutics targeting conditions such as Hepatitis B, breast carcinoma, liver fibrosis, liver carcinoma, and HIV. The company has established a strategic partnership with Quark Pharmaceuticals, Inc. to enhance its research and development capabilities.

ZIyan UAV

Series A in 2016
ZIYAN UAV is a research and development company focused on creating small and medium-sized electric unmanned helicopters, designed for a variety of civilian applications. These helicopters are utilized in sectors such as power line inspection, public security, mining, and mapping, as well as logistics and rescue operations. The company emphasizes high speed, significant maximum takeoff weight, and operational efficiency in its products. ZIYAN UAV integrates advanced technologies, including moving base technology, swarm technology, artificial intelligence modules, and a software-as-a-service system, alongside cloud capabilities. This integration enables the development of Internet of Things platforms that facilitate easier data access and intelligent decision-making for users.

UWorld

Series A in 2016
UWorld is a mobile merchant platform that provides billing services.

Replays

Angel Round in 2015
Replays is an e-sports comprehensive website mainly provides content such as sports video, industry news, tactical reports, and interviews.

Laviana Pharma

Series A in 2014
Laviana Pharma Co., Ltd. founded in 2005 is a high-tech enterprise. It specializes in providing process and manufacture outsourcing services (CDMO) for the pharmaceutical industry. The main scope of services covers all chemistry-related aspects of process development and transformation for the innovative drug substances and products from laboratory scale to commercialized scale, including process research, process development, process optimization, pilot production and large-scale production of intermediates, API starting materials and API (active pharmaceutical ingredient) for pre-clinical, clinical trial materials and commercialized products. It also provides CMC services for IND and NDA submission of innovative developmental drug. It has three wholly-owned subsidiary, namely, Beijing laviana Pharmatech Co., Ltd., Laviana (Tianjin) Pharmatech Development Co., Ltd., and Laviana Corporation incorporated in United States.

SolarVista Media

Series D in 2013
SolarVista Media Co., Ltd is a Chinese company specializing in outdoor advertising through innovative billboards. The company offers DCP billboards that utilize natural light to display digital images, allowing for seamless electronic updates without generating plastic waste during campaign transitions. This environmentally friendly approach positions SolarVista Media as a forward-thinking player in the advertising industry, focusing on sustainable practices while delivering effective advertising solutions.

Palmap

Series B in 2013
Palmap, Inc. is an indoor map service provider based in Shanghai, China, dedicated to offering indoor localization and navigation services. Established in 2012, the company has built the largest indoor map database in China, comprising 20,000 indoor maps and 3.5 million points of interest across 350 cities and 79 building types. Palmap specializes in delivering professional indoor mapping, positioning, and data analysis services tailored for commercial complexes, tourist attractions, hospitals, transportation hubs, and educational institutions. Its advanced map engine supports various formats, including 2D, 2.5D, and 3D, enabling features such as rotating, zooming, and navigation. The company employs modern positioning technologies using WiFi and Bluetooth Low Energy (BLE), achieving positioning accuracy of 3-5 meters and 1-3 meters, respectively. By analyzing positioning data, Palmap assists operators in enhancing management practices, enabling precision marketing, and optimizing service standards.

Baiwan

Series A in 2013
Baiwan is an interactive entertainment platform. They provide mobile terminal users with quality content such as small games, animations, MTV, web games, and online entertainment. They make web games more colorful, ubiquitous, and fun. They offer smart phone software based on android, symbian and apple systems.

Hisign Technology

Series C in 2012
Beijing Hisign Technology Co., Ltd., established in 1998, is a leading enterprise in China's multi-biometrics industry. The company is recognized for its advanced technologies in face recognition, fingerprint identification, palm print matching, handwriting recognition, and vehicle license plate recognition. Hisign is ISO 9001, ISO/IEC 20000-1, and ISO/IEC 27001 certified, reflecting its commitment to quality and security. Its diverse product offerings span multiple sectors, including public security for criminal investigations, forensics, and border control, as well as civil applications in finance, social security, education, transportation, and event management. Hisign's solutions integrate big data analysis for financial risk prevention and control, making it a comprehensive provider of biometric identification technologies in China.

AISpeech

Series A in 2012
AISpeech is a technology startup focused on enhancing human-machine interaction through advanced voice interaction technology. The company specializes in computer speech recognition, tone analysis, and dialog management techniques. It develops a human-computer dialogue operating system and artificial intelligence chip modules aimed at improving various aspects of voice technology, including speech recognition, speech synthesis, natural language understanding, and voice-print recognition. By offering these innovative solutions, AISpeech enables clients to access intelligent and interactive natural language services, thereby facilitating more effective communication between humans and machines.

Global Gem Exchange

Angel Round in 2011
Global Gem Exchange is a third-party trading platform specializing in jewelry and jade, primarily focusing on the diamond market. The company facilitates the trading of diamonds and gems by connecting global suppliers directly with retailers, streamlining the process for both parties. This approach not only enhances access to a diverse range of gems but also allows retailers to expand their inventory and increase revenue potential. Through its platform, Global Gem Exchange aims to improve efficiency and transparency in the trading of precious stones within the global market.

Shenogen Pharma Group

Series A in 2011
Shenogen Pharma Group is a drug discovery and development company.

ChineseAll Digital Publishing

Venture Round in 2010
Chinese Online (中文在线) is a company focused on digital publishing. It provides digital reading products to mobile phones, hand-held terminals, and the internet as well as other media. Chinese Online takes copyright organizations and authors as the genuine digital content source, and collaborates with them to manage the content. It also offers value-added services of digital content such as copyright derivatives and more. As a leading enterprise of digital publishing domestically, Chinese Online has established a complete media publishing model of unique content, variety in media and synchronized publishing.

UNIFLY

Post in 2010
Beijing Unifly Scientific and Technology Company Limited specializes in the research, development, manufacturing, and sale of automotive maintenance products, focusing on environmentally-friendly solutions. Founded in 1995 and headquartered in Beijing, China, the company offers a range of products including filters, low-carbon lubricants, glass cleaners, and antifreeze coolants. Its product offerings cater to various industries such as transportation, automobile parts, mining, metallurgy, and power generation. Unifly is committed to energy-saving and environmental protection, providing innovative materials and technologies that help vehicle owners maintain their cars while minimizing ecological impact. The company also has a research and development center located in Langfang, China, further enhancing its capabilities in developing new material technologies and derivative products.

UNIFLY

Angel Round in 2007
Beijing Unifly Scientific and Technology Company Limited specializes in the research, development, manufacturing, and sale of automotive maintenance products, focusing on environmentally-friendly solutions. Founded in 1995 and headquartered in Beijing, China, the company offers a range of products including filters, low-carbon lubricants, glass cleaners, and antifreeze coolants. Its product offerings cater to various industries such as transportation, automobile parts, mining, metallurgy, and power generation. Unifly is committed to energy-saving and environmental protection, providing innovative materials and technologies that help vehicle owners maintain their cars while minimizing ecological impact. The company also has a research and development center located in Langfang, China, further enhancing its capabilities in developing new material technologies and derivative products.

Achievo

Series B in 2007
Achievo is a provider of specialized IT services and solutions, catering to a global clientele primarily in the information technology sector. The company focuses on delivering software development services and embedded platforms, with an emphasis on enhancing the efficiency and cost-effectiveness of IT initiatives. By reducing risk in project execution, Achievo enables its clients to improve profitability and foster business growth.

Sumavision

Series D in 2006
Beijing Sumavision Co., Ltd. is a prominent Chinese high-tech company specializing in digital television software and systems. It stands out as the only provider of comprehensive digital TV solutions and offers a one-stop service for its clients. Sumavision has maintained the top position in the domestic market for front-end hardware products for seven consecutive years, capturing 50% of the market share in national digital TV translation provinces. Its products are utilized across 43 provinces and regions in China, supporting over 40 national and provincial broadcast systems, as well as more than 700 city and county TV stations. Sumavision's market share in China leads among similar products, while internationally, its offerings have been exported to over 70 countries, with Europe and North America accounting for a significant portion of its overseas trade. The company is engaged in the research, development, and production of a wide range of digital television products, including head-end hardware, encoding and transcoding solutions, and IPTV/OTT systems.

Beijing ACCB Biotech

Series A in 2005
Beijing ACCB Biotech Ltd. specializes in the research and development of cancer detection methods utilizing molecular biology technologies. The company offers a range of services centered on personalized therapy, including early cancer screening, drug selection, effect tracking, prognostic evaluation, and monitoring for transfer and recurrence. ACCB Biotech's product lineup features various diagnostic tools, such as EnzymAct and Gene 21 of Breast Cancer, along with automated workstations for nucleic acid extraction. The company operates facilities exceeding 3,000 square meters, meeting stringent cleanliness standards. Established in June 2009, ACCB Biotech's EnzymAct® received approval from the State Food and Drug Administration, marking a significant milestone in its commitment to developing advanced molecular diagnostic products for precision medicine and individualized treatment plans.

Sumavision

Series B in 2001
Beijing Sumavision Co., Ltd. is a prominent Chinese high-tech company specializing in digital television software and systems. It stands out as the only provider of comprehensive digital TV solutions and offers a one-stop service for its clients. Sumavision has maintained the top position in the domestic market for front-end hardware products for seven consecutive years, capturing 50% of the market share in national digital TV translation provinces. Its products are utilized across 43 provinces and regions in China, supporting over 40 national and provincial broadcast systems, as well as more than 700 city and county TV stations. Sumavision's market share in China leads among similar products, while internationally, its offerings have been exported to over 70 countries, with Europe and North America accounting for a significant portion of its overseas trade. The company is engaged in the research, development, and production of a wide range of digital television products, including head-end hardware, encoding and transcoding solutions, and IPTV/OTT systems.

Sumavision

Series A in 2001
Beijing Sumavision Co., Ltd. is a prominent Chinese high-tech company specializing in digital television software and systems. It stands out as the only provider of comprehensive digital TV solutions and offers a one-stop service for its clients. Sumavision has maintained the top position in the domestic market for front-end hardware products for seven consecutive years, capturing 50% of the market share in national digital TV translation provinces. Its products are utilized across 43 provinces and regions in China, supporting over 40 national and provincial broadcast systems, as well as more than 700 city and county TV stations. Sumavision's market share in China leads among similar products, while internationally, its offerings have been exported to over 70 countries, with Europe and North America accounting for a significant portion of its overseas trade. The company is engaged in the research, development, and production of a wide range of digital television products, including head-end hardware, encoding and transcoding solutions, and IPTV/OTT systems.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.